Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Gynecologic 4Head & Neck 3Dermatologic 3Classical hematology 2Thoracic 1Sarcoma 1Myeloid 1Genitourinary 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 957Urinary Bladder Neoplasms 264Carcinoma, Renal Cell 251Kidney Neoplasms 147Carcinoma, Transitional Cell 129Breast Neoplasms 127Neoplasms 122Colorectal Neoplasms 97Ovarian Neoplasms 90Melanoma 85Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 81Neoplasm Metastasis 79Pancreatic Neoplasms 68Non-Muscle Invasive Bladder Neoplasms 68Uterine Cervical Neoplasms 58Stomach Neoplasms 55Head and Neck Neoplasms 51Squamous Cell Carcinoma of Head and Neck 47Endometrial Neoplasms 47Adenocarcinoma 45Esophageal Neoplasms 44Testicular Neoplasms 42Carcinoma, Hepatocellular 41Sarcoma 39Disease 33Triple Negative Breast Neoplasms 32Liver Neoplasms 30Colonic Neoplasms 29Metastatic Castration-resistant Prostate Cancer 25

Interventions

olaparib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hereditary Sensory and Autonomic Neuropathies × Genitourinary × Clear all
NCT04038502 2025-08-20

COBRA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡